BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells 1,597 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 1,597 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,925.00. Following the transaction, the executive vice president now directly owns 260,601 shares in the company, valued at approximately $6,515,025. The trade was a 0.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

BioLife Solutions Trading Up 3.7 %

BioLife Solutions stock traded up $0.92 during midday trading on Monday, reaching $25.92. The stock had a trading volume of 222,832 shares, compared to its average volume of 348,620. BioLife Solutions, Inc. has a twelve month low of $14.84 and a twelve month high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -24.45 and a beta of 2.04. The firm's fifty day simple moving average is $26.59 and its two-hundred day simple moving average is $25.49.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same period in the previous year, the company earned ($0.21) EPS. Equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Remove Ads

Institutional Trading of BioLife Solutions

Several hedge funds and other institutional investors have recently bought and sold shares of BLFS. Steward Partners Investment Advisory LLC acquired a new stake in BioLife Solutions in the 4th quarter valued at $26,000. Mark Sheptoff Financial Planning LLC bought a new position in BioLife Solutions during the third quarter worth about $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of BioLife Solutions in the 4th quarter valued at $31,000. Quest Partners LLC bought a new stake in BioLife Solutions during the 3rd quarter worth approximately $57,000. Finally, 1620 Investment Advisors Inc. raised its holdings in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after acquiring an additional 675 shares during the period. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BLFS has been the topic of several research analyst reports. Northland Securities raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. HC Wainwright boosted their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Benchmark reaffirmed a "buy" rating and issued a $30.00 target price on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, KeyCorp boosted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, BioLife Solutions has an average rating of "Moderate Buy" and an average price target of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.